APA (7th ed.) Citation

Lepper, A., Bitsch, R., Kurt, F. G. Ö., Arkhypov, I., Lasser, S., Utikal, J., & Umansky, V. Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Lepper, Alisa, Rebekka Bitsch, Feyza Gül Özbay Kurt, Ihor Arkhypov, Samantha Lasser, Jochen Utikal, and Viktor Umansky. Melanoma Patients with Immune-related Adverse Events After Immune Checkpoint Inhibitors Are Characterized by a Distinct Immunological Phenotype of Circulating T Cells and M-MDSCs. Taylor & Francis Group.

MLA (9th ed.) Citation

Lepper, Alisa, et al. Melanoma Patients with Immune-related Adverse Events After Immune Checkpoint Inhibitors Are Characterized by a Distinct Immunological Phenotype of Circulating T Cells and M-MDSCs. Taylor & Francis Group.